Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 31, Issue 1, 2008, Pages 49-54

  Hesdorffer, Mary E ^a,e   Chabot, John A ^a   Keohan, Mary Louise ^b   Fountain, Karen ^c   Talbot, Susan ^d   Gabay, Michelle ^a   Valentin, Catherine ^a   Lee, Shing M ^a   Taub, Robert N ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c Long Island Radiation Therapy ^*  (United States)

^d NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^e Mesothelioma Applied Research Foundation   (United States)

Author keywords

Intraperitoneal chemotherapy; Mesothelioma; Resection

Indexed keywords

ANTIBIOTIC AGENT; CISPLATIN; DOXORUBICIN; GAMMA1B INTERFERON; MITOMYCIN; PERCOCET; ANTINEOPLASTIC AGENT;

ABSCESS; ADULT; AGED; ARTICLE; ASPIRATION PNEUMONIA; BODY ACHE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CATHETER INFECTION; CHILL; CLINICAL ARTICLE; CYTOREDUCTIVE SURGERY; DRUG TOLERABILITY; EPITHELIUM CELL; FEMALE; FISTULA; FOLLOW UP; GASTROINTESTINAL TOXICITY; HISTOPATHOLOGY; HUMAN; IMMUNOTHERAPY; INTESTINE ULCER; LAPAROTOMY; MALE; MALIGNANT NEOPLASTIC DISEASE; MORTALITY; NAUSEA AND VOMITING; OTOTOXICITY; OVERALL SURVIVAL; PAIN; PERITONEUM MESOTHELIOMA; ROOM TEMPERATURE; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; SURVIVAL RATE; SYMPATHETIC DYSTROPHY; TEMPERATURE; THERAPY EFFECT; ABDOMINAL TUMOR; ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL; FEASIBILITY STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; MESOTHELIOMA; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PERITONEUM TUMOR; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME;

ABDOMINAL NEOPLASMS; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; CISPLATIN; COMBINED MODALITY THERAPY; DOXORUBICIN; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAPERITONEAL; MALE; MESOTHELIOMA; MIDDLE AGED; MITOMYCIN; PERITONEAL NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 42449085838     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3180684181     Document Type: Article

References (21)

1. Taub RN, Keohan ML, Chabot JC, et al. Peritoneal mesothelioma. Curr Treat Options Oncol. 2000;1:303-312.
2. Yan TD, Brun EA, Cerruto CA, et al. Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol. 2007;14:41-49.
3. Loggie B, Fleming R, McQuellon R, et al. Prospective trial for the treatment of malignant peritoneal mesothelioma. Am Surgeon. 2001;67:999.
4. Antman KH. Natural history and epidemiology of malignant mesothelioma. Chest. 1993;103(suppl 4):373-376.
5. Newmann V, Rutten A, Scharmach M, et al. Factors influencing longterm survival in mesothelioma patients: results of the German Mesothelioma Register. Int Arch Occup Environ Health. 2004;77:191-199.
6. Antman K, Shemin R, Ryan L, et al. Malignant mesothelioma: prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham an Women's Hospital experience over two decades, 1965-1985. J Clin Oncol. 1988;6:147-153.
7. Lomas DA, Wallis PJ, Stockley RA. Palliation of malignant ascites with a Tenckhoff catheter. Thorax. 1989;44:828.
8. Lederman GS, Recht A, Herman T, et al. Long-term survival in peritoneal mesothelioma: the role of radiotherapy and combined modality treatment. Cancer. 1987;59:1882-1886.
9. Baas P. Chemotherapy for malignant mesothelioma: from doxorubicin to vinorelbine. Semin Oncol. 2002;29:62-69.
10. Berghmans T, Paesmans M, Lalami Y, et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer. 2002;38:111-121.
11. Vogelzang N, Rusthoven J, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21: 2636-2643.
12. Antman K, Osteen R, Klegar K, et al. Early peritoneal mesothelioma: a treatable malignancy. Lancet. 1985;2:977-982.
13. Weissman L, Osteen R, Corson J, et al. Combined modality therapy for intraperitoneal mesothelioma. Proc Am Soc Clin Oncol. 1988;7:274.
14. Boutin C, Nussbaum E, Monnet I, et al. Intrapleural treatment with recombinant gamma-interferon in early stage malignant pleural mesothelioma. Cancer. 1994;74:2460-2467.
15. Windbichler GH, Hausmaninger H, Stummvoll W, et al. Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer. 2000;82:1138-1144.
16. Freedman RS, Kudelka AP, Kavanagh JJ, et al. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma. Clin Cancer Res. 2000;6:2268-2278.
17. Ma GY, Bartlett DL, Reed E, et al. Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma. Cancer J Sci Am. 1997;3:174-179.
18. Park BJ, Alexander HR, Libutti SK, et al. Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol. 1999;6:582-590.
19. Mongero LB, Beck JR, Kroslowitz RM, et al. Treatment of primary peritoneal mesothelioma by hyperthemic intraperitoneal chemotherapy. Perfusion. 1999;14:141-145.
20. Ceresoli G, Locati L, Ferreri A, et al. Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma. Lung Cancer. 2001;32:279-287.
21. Deraco M, Casali P, Inglese MG, et al. Peritoneal mesothelioma treated by induction chemotherapy, cytoreductive surgery, and intraperitoneal hyperthermic perfusion. J Surg Oncol. 2003;83:147-153.